Financial Performance Overview

Procter & Gamble Health Limited announced its unaudited financial results for the quarter ended June 30, 2026 (Q1 FY2027). The company reported strong growth in both top-line and bottom-line performance.

Revenue Performance:

  • Sales: ₹356 crores
  • Year-over-Year Growth: +7% versus Q1 FY2026

Profitability Metrics:

  • Reported Profit After Tax (PAT): ₹96 crores
  • Year-over-Year PAT Growth: +45% versus Q1 FY2026
  • Operational Profit After Tax (PAT): ₹72 crores (excluding one-time proceeds)
  • Operational PAT Growth: +9% versus year ago (excluding one-time proceeds)

Performance Drivers

The sales growth of 7% was driven by:

  • Strong brand fundamentals
  • Superior retail execution
  • Positive consumer response to new innovations

The significant PAT growth of 45% was led by:

  • Growth in sales
  • Strengthened supply chain capabilities
  • Enhanced go-to-market capabilities
  • One-time proceeds from the sale of an immovable asset

Management Commentary

Mr. Milind Thatte, Managing Director, P&G Health India, stated that the company started Financial Year 2026-2027 strongly, carrying forward the growth momentum from the previous fiscal. He emphasized:

  • Sustained top-line and bottom-line growth
  • Consumer response to science-backed superior innovations
  • New consumer communication initiatives
  • Strengthened go-to-market and supply chain capabilities

The company's strategy focuses on:

  • Focused portfolio of quality, trusted, and highly recommended brands
  • Superiority across product, package, brand communication, retail execution, and value
  • Constructive disruption
  • Productivity improvements
  • Agile accountable organization

Business Context

Procter & Gamble Health Limited is one of India's largest vitamins, minerals, and supplements (VMS) companies, manufacturing and marketing VMS products including Neurobion, Livogen, SevenSeas, Evion, Polybion, and Nasivion for healthy lifestyle and improved quality of life.

The results were approved at a meeting of the Board of Directors held on August 6, 2026, and submitted to both BSE Limited and National Stock Exchange of India Limited.